# Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct07458204/  
OnCo record `nct07458204` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Institut Jean-Godinot, not yet recruiting.

## Summary

Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT07458204 by Institut Jean-Godinot, with a registry enrolment figure of 760 participants, started 2026-10-01 and due to reach its primary completion in 2031-10-01. Interventions recorded: LVB infiltration. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: "* with histologically confirmed triple-negative breast cancer". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: EPPIL
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07458204
- Phase: 2
- Setting: Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer
- Sponsor: Institut Jean-Godinot
- Enrolled: 760

## Sources

- ClinicalTrials.gov NCT07458204: https://clinicaltrials.gov/study/NCT07458204

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07458204.json